Theranostic systems assembled in situ on demand by host-guest chemistry

Biomaterials

Volumn 32, Issue 30, 2011, Pages 7687-7694

  Jung, Hyuntae ^a   Park, Kyeng Min ^a   Yang, Jeong A ^a   Oh, Eun Ju ^a   Lee, Don Wook ^a   Park, Kitae ^a   Ryu, Sung Ho ^a   Hahn, Sei Kwang ^a   Kim, Kimoon ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

Cucurbituril; Host guest chemistry; Hyaluronic acid; Multi functionality; Theranostic system

Indexed keywords

CUCURBITURILS; HOSTGUEST CHEMISTRY; HYALURONIC ACIDS; MULTIFUNCTIONALITY; THERANOSTIC SYSTEM;

DRUG DELIVERY; DRUG INTERACTIONS; IMPLANTS (SURGICAL); NANOPARTICLES; ORGANIC ACIDS; PEPTIDES; TISSUE; TISSUE ENGINEERING;

SIGNAL TRANSDUCTION;

CALCIUM ION; CUCURBIT[6]URIL CONJUGATED HYALURONATE; FLUORESCEIN ISOTHIOCYANATE; FORMYLPEPTIDE RECEPTOR LIKE 1; HYALURONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; SPERMIDINE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; BIOTECHNOLOGY; CELL STRAIN; CELL STRAIN B16F1; CELL STRAIN MCF 7; CONTROLLED STUDY; HOST GUEST INTERACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR INTERACTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNTHESIS; THERANOSTIC SYSTEM;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CELL LINE, TUMOR; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; HYALURONIC ACID; IMIDAZOLES; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; SPERMIDINE;

EID: 80051545755     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.06.060     Document Type: Article

References (33)

1. Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci Polym Symp 1975, 51:135-153.
2. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Disc 2003, 2:347-360.
3. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Disc 2008, 7:771-782.
4. Stuart M.A.C., Huck W.T.S., Genzer J., Muller M., Ober C., Stamm M., et al. Emerging applications of stimuli-responsive polymer materials. Nat Mater 2010, 9:101-113.
5. Prescott J.H., Lipka S., Baldwin S., Sheppard N.F., Maloney J.M., Coppeta J., et al. Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat Biotech 2006, 24:437-438.
6. Yavuz M.S., Cheng Y., Chen J., Cobley C.M., Zhang Q., Rycenga M., et al. Gold nanocages covered by smart polymers for controlled release with near-infrared light. Nat Mater 2009, 8:935-939.
7. Horcajada P., chalati T., Serre C., Gillet B., Sebrie C., Baati T., et al. Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat Mater 2010, 9:172-178.
8. Wamer S. Strategy requires teamwork, partnering, and tricky regulatory maneuvering. The Scientist 2004, 18:38.
9. Liechty W.B., Kryscio D.R., Slaughter B.V., Peppas N.A. Polymers for drug delivery systems. Annu Rev Chem Biomol Eng 2010, 1:149-173.
10. Pillai O., Panchagnula R. Polymers in drug delivery. Curr Opin Chem Biol 2001, 5:447-451.
11. Satchi-Fainaro R., Wrasidlo W., Lode H.N., Shabat D. Synthesis and characterization of a catalytic antibody-HPMA copolymer-conjugate as a tool for tumor selective prodrug activation. Bioorg Med Chem 2002, 10:3023-3029.
12. Gu F., Zhang L., Teply B.A., Mann N., Wang A., Radovic-Moreno A.F., et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 2008, 105:2586-2591.
13. Vandenbroucke R.E., Smedt S.C., Demeester J., Sanders N.N. Cellular entry pathway and gene transfer capacity of TAT-modified lipoplexes. Biochim Biophys Acta 2007, 1768:571-579.
14. Xiang G., Wu J., Lu Y., Liu Z., Lee R.J. Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes. Int J Pharm 2008, 356:29-36.
15. Davis M.E., Brewster M.E. Cyclodextrin-based pharmaceutics: Past, present, future. Nat Rev Drug Disc 2004, 3:1023-1035.
16. Davis M.E., Zuckeman J.E., Choi C.H.J., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1071.
17. Bellocq N.C., Pun S.H., Jensen G.S., Davis M.E. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 2003, 14:1122-1132.
18. Mock W.L. Cucurbituril. Top Curr Chem 1995, 175:1-24.
19. Kim K. Mechanically interlocked molecules incorporating cucurbituril and their supramolecular assemblies. Chem Soc Rev 2002, 31:96-107.
20. Lee J.W., Samal S., Selvapalam N., Kim H.J., Kim K. Cucurbituril homologues and derivatives: new opportunities in supramolecular chemistry. Acc Chem Res 2003, 36:621-630.
21. Lagona J., Mukhopadhyay P., Chakrabarti S., Isaacs L. The cucurbit[n]uril family. Angew Chem 2005, 117:4922-4949.
22. Kim Y., Kim H., Ko Y.H., Selvapalam N., Rekharsky M.V., Inoue Y., et al. Complexation of aliphatic ammonium ions with a water-soluble cucurbit[6]uril derivative in pure water: isothermal calorimetric, NMR, and X-ray crystallographic study. Chem Eur J 2009, 15:6143-6151.
23. Liu S., Ruspic C., Mukhopadhyay P., Chakrabarti S., Zavalij P.Y., Isaacs L. The cucurbit[n]uril family: prime components for self-sorting systems. J Am Chem Soc 2005, 127:15959-15967.
24. Park K.M., Suh K., Jung H., Lee D.W., Ahn Y., Kim J., et al. Cucurbituril-based nanoparticles: a new efficient vehicle for targeted intracellular delivery of hydrophobic drugs. Chem Commun 2009, 71-73.
25. Park K.M., Lee D.W., Sarkar B., Jung H., Kim J., Ko Y.H., et al. Reduction-sensitive, robust vesicles with a non-covalently modifiable surface as a multifunctional drug-delivery platform. Small 2010, 6:1430-1441.
26. Kim K.S., Hur W., Park S.J., Hong S.W., Choi J.E., Goh E.J., et al. Bioimaging for targeted delivery of hyaluronic acid derivatives to the livers in cirrhotic mice using quantum dots. ACS Nano 2010, 4:3005-3014.
27. Park K., Lee M.Y., Kim K.S., Hahn S.K. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate. Biomaterials 2010, 31:5258-5265.
28. Aruffo A., Stamenkovic I., Melnick M., Underhill C., Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990, 6:1303-1313.
29. Entwistle J., Hall C.L., Turley E.A. HA receptors: Regulators of signaling to the cytoskeleton. J Cell Biochem 1998, 61:569-577.
30. Schledzewski K., Falkowski M., Moldenhauer G., Metharom P., Kzhyshkowska J., Ganss R., et al. Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. J Pathol 2006, 209:67-77.
31. Oh E.J., Park K., Kim K.S., Kim J., Yang J.A., Kong J.H., et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release 2010, 141:2-12.
32. Jon S.Y., Selvapalam N., Oh D.H., Kang J.K., Kim S.Y., Jeon Y.J., et al. Facile synthesis of cucurbit[n]uril derivatives via direct functionalization: expanding utilization of cucurbit[n]uril. J Am Chem Soc 2003, 125:10186-10187.
33. Bae Y.S., Lee H.Y., Jo E.J., Kim J.I., Kang H.K., Ye R.D., et al. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J Immunol 2004, 173:607-614.